Essais Cliniques Actuels
Clinical Trials
| Study Title | Minimum Age | Maximum age | Who Can Join? | Phase | Status |
|---|---|---|---|---|---|
| Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate (BIA-2093-213) Epilepsy, stroke |
30 | 80 |  All |
2 | Recruitment terminated |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene (BIA-28-6156-201) Parkinson Disease, GBA1 gene, Pathogenic variant |
35 | 80 | All |
2 | Recruitment terminated |
| A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label Extension (BIA-91067-303) Early Parkinson Disease |
30 | 80 | All |
3 | Recruitment terminated |
| Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain (BIA-91067-404) Parkinson Disease, Motor fluctuations, Pain |
30 | n.a. | All |
4 | Recruitment terminated |